Application of cells of cord blood and umbilical cord: achievements, challenges and perspectives
I. V. Gilevich,
I. S. Polyakov,
V. A. Porhanov,
A. P. Storozhuk,
A. G. Zavgorodnyaya,
E. A. Kolomiytseva,
A. S. Sotnichenko https://doi.org/10.35401/2541-9897-2022-25-2-67-76
Abstract
This review focuses on the biological aspects of the use of cord blood as a valuable source of cells. The distinctive features of hematopoietic stem cells, cells of the immune system, mesenchymal stem cells are described. The analysis of the results of clinical research and development of therapeutic approaches using cord blood cells and umbilical cord for the treatment of various diseases has been carried out.
Currently, the target area of cord blood research is hematopoietic stem cell transplantation, as well as cellular immunotherapy of tumor diseases, treatment of neurological diseases and regenerative medicine.
About the Authors
I. V. Gilevich
Scientific Research Institute - Ochapovsky Regional Clinical Hospital no. 1; Kuban State Medical University
Russian Federation
Russian Federation
Irina V. Gilevich, Cand. Sci. (Med.), Head of the Laboratory for Development and Study of New Treatment Technologies; Assistant Professor, Department of Oncology with the Course of Thoracic Surgery, Faculty of Advanced Training and Professional Retraining of Specialists
1 Maya str., 167, Krasnodar, 350086
Krasnodar
I. S. Polyakov
Scientific Research Institute - Ochapovsky Regional Clinical Hospital no. 1; Kuban State Medical University
Russian Federation
Russian Federation
Igor S. Polyakov, Cand. Sci. (Med.), First Deputy Chief Physician; Assistant Professor, Department of Oncology with the Course of Thoracic Surgery, Faculty of Advanced Training and Professional Retraining of Specialists
Krasnodar
V. A. Porhanov
Scientific Research Institute - Ochapovsky Regional Clinical Hospital no. 1; Kuban State Medical University
Russian Federation
Russian Federation
Vladimir A. Porhanov, Academician of Russian Academy of Sciences, Dr. Sci. (Med.), Professor, Chief Doctor; Head of Department of Oncology with the Course of Thoracic Surgery, Faculty of Advanced Training and Professional Retraining of Specialists
Krasnodar
A. P. Storozhuk
Kuban State Medical University; Krasnodar Maternity Hospital
Russian Federation
Russian Federation
Alexander P. Storozhuk, Dr. Sci. (Med.), Head of Krasnodar Maternity Hospital, Professor of the Department of Fundamental and Clinical Biochemistry
Krasnodar
A. G. Zavgorodnyaya
Kuban State Medical University
Russian Federation
Russian Federation
Anna G. Zavgorodnyaya, 6th year student, Medical Faculty
Krasnodar
E. A. Kolomiytseva
Scientific Research Institute - Ochapovsky Regional Clinical Hospital no. 1
Russian Federation
Russian Federation
Elena A. Kolomiytseva, Biologist, Laboratory for Development and Study of New Treatment Technologies
Krasnodar
A. S. Sotnichenko
Kuban State Medical University
Russian Federation
Russian Federation
Alexander S. Sotnichenko, Cand. Sci. (Med.), Associate Professor, Department of Pathological Anatomy
Krasnodar
References
1. Romanov YuA, Romanov AYu. Tissues of perinatal origin is a unique source of cells for regenerative medicine. Part I. Cord blood. Neonatology: News, Opinions, Training. 2018;6(2):64-77. (In Russ.). https://doi.org/10.24411/2308-2402-2018-00019
2. Berglund S, Magalhaes I, Gaballa A, et al. Advances in um-bilical cord blood cell therapy: the present and the future. Expert Opin Biol Ther. 2017;17(6):691-699. PMID: 28379044. https://doi.org/10.1080/14712598.2017.1316713
3. Topful M, Qetin i. Stem Cells in Cell Therapy and Regenerative Medicine. International OMICS eBooks; 2018. https://doi.org/10.4172/978-1-63278-021-8-22
4. Abdulrazzak H, Moschidou D, Jones G, et al. Biological characteristics of stem cells from foetal, cord blood and extraem- bryonic tissues. J R Soc Interface. 2010;7(Suppl 6):S689-706. PMID: 20739312. PMCID: PMC2988276. https://doi.org/10.1098/rsif.2010.0347.focus
5. Gluckman E. History of cord blood transplantation. Bone Marrow Transplant. 2009;44(10):621-626. PMID: 19802032. https://doi.org/10.1038/bmt.2009.280
6. Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: the first 25 years and beyond. Blood. 2013;122(4):491-498. PMID: 23673863. PMCID: PMC3952633. http://dx.doi.org/10.1182/blood-2013-02-453175
7. Alatyyat SM, Alasmari HM, Aleid OA, et al. Umbilical cord stem cells: Background, processing and applications. Tissue Cell. 2020;65:101351. PMID: 32746993. https://doi.org/10.1016/j.tice.2020.101351
8. Gupta A, El-Amin 3rd SF, Levy HJ, et al. Umbilical cord- derived Wharton's jelly for regenerative medicine applications. J Orthop Surg Res. 2020;15(1):49. PMID: 32054483. PMCID: PMC7017504. https://doi.org/10.1186/s13018-020-1553-7
9. Zhu X, Tang B, Sun Z. Umbilical cord blood transplantation: Still growing and improving. Stem Cells Transl Med. 2021;Suppl 2:S62-S74. PMID: 34724722. PMCID: PMC8560197. https://doi.org/10.1002/sctm.20-0495
10. Hordyjewska A, Popiolek L, Horecka A. Characteristics of hematopoietic stem cells of umbilical cord blood. Cytotechnology. 2015;67(3):387-396. PMID: 25373337. PMCID: PMC4371573. https://doi.org/10.1007/s10616-014-9796-y
11. Yun HD, Varma A, Hussain MJ, et al. Clinical Relevance of Immunobiology in Umbilical Cord Blood Transplantation. J Clin Med. 2019;8(11):1968. PMID: 31739455. PMCID: PMC6912281. https://doi.org/10.3390/jcm8111968
12. Nomura A, Takada H, Jin CH, et al. Functional analyses of cord blood natural killer cells and T cells: a distinctive inter- leukin-18 response. Exp Hematol. 2001;29(10):1169-1176. PMID: 11602318. https://doi.org/10.1016/s0301-472x(01)00689-0
13. Romanov YuA, Romanov AYu. Tissues of perinatal origin: a unique source of cells for regenerative medicine. Part II. Umbilical cord. Neonatology: News, Opinions, Training. 2018;6(3):54-73. (In Russ.). https://doi.org/10.24411/2308-2402-2018-13002
14. Dominici M, Le Blanc K, Mueller I, et al. Minimal cri¬teria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317. PMID: 16923606. https://doi.org/10.1080/14653240600855905
15. Silini AR, Di Pietro R, Lang-Olip I, et al. Perinatal Derivatives: Where Do We Stand? A Roadmap of the Human Placenta and Consensus for Tissue and Cell Nomenclature. Front Bioeng Biotechnol. 2020;8:610544. PMID: 33392174. PMCID: PMC7773933. https://doi.org/10.3389/fbioe.2020.610544
16. Torre P, Flores AI. Current Status and Future Prospects of Perinatal Stem Cells. Genes (Basel). 2020;12(1):6. PMID: 33374593. PMCID: PMC7822425. https://doi.org/110.3390/genes12010006
17. Forraz N, McGuckin CP. The umbilical cord: a rich and ethical stem cell source to advance regenerative medicine. Cell Prolif. 2011;44 Suppl 1:60-69. PMID: 21481046. PMCID: PMC6495455. https://doi.org/10.1111/j.1365-2184.2010.00729.x
18. Xie Q, Liu R, Jiang J, et al. What is the impact of human umbilical cord mesenchymal stem cell transplantation on clinical treatment? Stem Cell Res Ther. 2020;11(1):519. PMID: 33261658. PMCID: PMC7705855. https://doi.org/10.1186/s13287-020-02011-z
19. Blazar BR, Hill GR, Murphy WJ. Dissecting the biol¬ ogy of allogeneic HSCT to enhance the GvT effect whilst mini-mizing GvHD. Nat Rev Clin Oncol. 2020;17(8):475-492. PMID: 32313224. PMCID: PMC7901860. https://doi.org/10.1038/s41571-020-0356-4
20. Stavropoulos-Giokas C, Dinou A, Papassavas A. The Role of HLA in Cord Blood Transplantation. Bone Marrow Res. 2012;2012:485160. PMID: 23097706. PMCID: PMC3477523. http://doi.org/10.1155/2012/485160
21. Kindwall-Keller TL, Ballen KK. Umbilical cord blood: The promise and the uncertainty. Stem Cells Transl Med. 2020;9(10):1153-1162. PMID: 32619330. PMCID: PMC7519764. https://doi.org/10.1002/sctm.19-0288
22. World Marrow Donor Association International Standards for Unrelated Hematopoietic Stem Cell Donor Registries. D3.1 Public webpages with cord blood banking practices as part of the 2019 work programme of the World Marrow Donor Association (WMDA) for the EU Third Health Programme (2014-2020). 2020:26. URL: https://wmda.info/wp-content/uploads/2021/01/WMDA-2020-Standards_AM1_Jan2021-1.pdf
23. Mayani H, Wagner JE, Broxmeyer HE. Cord blood re-search, banking, and transplantation: achievements, challenges, and perspectives. Bone Marrow Transplant. 2020;55(1):48-61. PMID: 31089283. https://doi.org/10.1038/s41409-019-0546-9
24. Song CG, Zhang YZ, Wu HN, et al. Stem cells: a promis-ing candidate to treat neurological disorders. Neural Regen Res. 2018;13(7):1294-1304. PMID: 30028342. PMCID: PMC6065243. https://doi.org/10.4103/1673-5374.235085
25. Paton MCB, Wall DA, Elwood N, et al. Safety of alloge-neic umbilical cord blood infusions for the treatment of neurologi-cal conditions: a systematic review of clinical studies. Cytotherapy. 2022;24(1):2-9. PMID: 34384698. https://doi.org/10.1016/j.jcyt.2021.07.001
26. Balassa K, Rocha V. Anticancer cellular immunothera¬pies derived from umbilical cord blood. Expert Opin Biol Ther. 2018;18(2):121-134. PMID: 29103317. https://doi.org/10.1080/14712598.2018.1402002
27. Mu YX, Zhao YX, Li BY, et al. A simple method for in vitro preparation of natural killer cells from cord blood. BMC Biotechnol. 2019;19(1):80. PMID: 31752805. PMCID: PMC6869212. https://doi.org/10.1186/s12896-019-0564-0
28. Wang Z, Wu Z, Liu Y, et al. New development in CAR-T cell therapy. J Hematol Oncol. 2017;10(1):53. PMID: 28222796. PMCID: PMC5320663. https://doi.org/10.1186/s13045-017-0423-1
29. Obajdin J, Davies DM, Maher J. Engineering of chime¬ric natural killer cell receptors to develop precision adoptive im-munotherapies for cancer. Clin Exp Immunol. 2020;202(1):11-27. PMID: 32544282. PMCID: PMC7488126. https://doi.org/10.1111/cei.13478
30. Liu E, Marin D, Banerjee P, et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med. 2020;382(6):545-553. PMID: 32023374. PMCID: PMC7101242. https://doi.org/10.1056/NEJMoa1910607
31. Kulus M, Sibiak R, Stefanska K, et al. Mesenchymal Stem/Stromal Cells Derived from Human and Animal Perinatal Tissues-Origins, Characteristics, Signaling Pathways, and Clinical Trials. Cells. 2021;10(12):3278. PMID: 34943786. PMCID: PMC8699543. https://doi.org/10.3390/cells10123278
32. Mebarki M, Abadie C, Larghero J, et al. Human umbilical cord-derived mesenchymal stem/stromal cells: a promising candi-date for the development of advanced therapy medicinal products. Stem Cell Res Ther. 2021;12(1):152. PMID: 33637125. PMCID: PMC7907784. https://doi.org/10.1186/s13287-021-02222-y
33. Thompson M, Mei SHJ, Wolfe D, et al. Cell therapy with intravascular administration of mesenchymal stromal cells contin-ues to appear safe: An updated systematic review and meta-analysis. E Clinical Medicine. 2020;19:100249. PMID: 31989101. PMCID: PMC6970160. https://doi.org/10.1016/j.eclinm.2019.100249
34. Wu Y, Cao Y, Li X, et al. Cotransplantation of haploidenti- cal hematopoietic and umbilical cord mesenchymal stem cells for severe aplastic anemia: successful engraftment and mild GVHD. Stem Cell Res. 2014;12(1):132-138. PMID: 24185180. https://doi.org/10.1016/j.scr.2013.10.001
35. Riordan NH, Morales I, Fernandez G, et al. Clinical feasi-bility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis. J Transl Med. 2021;19(1):197. PMID: 29523171. PMCID: PMC5845260. https://doi.org/10.1186/s12967-018-1433-7
36. Wang D, Niu L, Feng X, et al. Long-term safety of um-bilical cord mesenchymal stem cells transplantation for systemic lupus erythematosus: a 6-year follow-up study. Clin Exp Med. 2017;17(3):333-340. PMID: 27270729. https://doi.org/10.1007/s10238-016-0427-0
37. Yin Y, Hao H, Cheng Y, et al. The homing of human um-bilical cord-derived mesenchymal stem cells and the subsequent modulation of macrophage polarization in type 2 diabetic mice. Int Immunopharmacol. 2018;60:235-245. PMID: 29778021. https:// doi.org/10.1016/j.intimp.2018.04.051
38. Cai J, Wu Z, Xu X, et al. Umbilical Cord Mesenchymal Stromal Cell With Autologous Bone Marrow Cell Transplantation in Established Type 1 Diabetes: A Pilot Randomized Controlled Open-Label Clinical Study to Assess Safety and Impact on Insulin Secretion. Diabetes Care. 2016;39(1):149-157. PMID: 26628416. https://doi.org/10.2337/dc15-0171
39. Dilogo IH, Canintika AF, Hanitya AL, et al. Umbilical cord-derived mesenchymal stem cells for treating osteoarthritis of the knee: a single-arm, open-label study. Eur J Orthop Surg Traumatol. 2020;30(5):799-807. PMID: 31989258. https://doi.org/10.1007/s00590-020-02630-5
40. Kim YJ, Ahn HJ, Lee SH, et al. Effects of conditioned media from human umbilical cord blood-derived mesenchymal stem cells in the skin immune response. Biomed Pharmacother. 2020;131:110789. PMID: 33152947. https://doi.org/10.1016/j.bio-pha.2020.110789
41. Zhang J, Lv S, Liu X, et al. Umbilical Cord Mesenchymal Stem Cell Treatment for Crohn's Disease: A Randomized Controlled Clinical Trial. Gut Liver. 2018;12(1):73-78. PMID: 28873511. PMCID: PMC5753687. https://doi.org/10.5009/gnl17035
42. Sun Q, Huang Z, Han F, et al. Allogeneic mesenchymal stem cells as induction therapy are safe and feasible in renal al-lografts: pilot results of a multicenter randomized controlled trial. J Transl Med. 2018;16(1):52. PMID: 29514693. PMCID: PMC5842532. https://doi.org/10.1186/s12967-018-1422-x
43. Shi M, Liu Z, Wang Y, et al. A Pilot Study of Mesenchymal Stem Cell Therapy for Acute Liver Allograft Rejection. Stem Cells Transl Med. 2017;6(12):2053-2061. PMID: 29178564. PMCID: PMC5702514. https://doi.org/10.1002/sctm.17-0134
44. Stukan AI, Gilevich IV, Porhanov VA, et al. Pathogenetic ra-tionale for the use of cell therapy in lung injury associated with SARS-CoV-2. Innovative Medicine of Kuban. 2020;(2):69-78. (In Russ.). https://doi.org/10.35401/2500-0268-2020-18-2-69-78
45. Shu L, Niu C, Li R, et al. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells. Stem Cell Res Ther. 2020;11(1):361. PMID: 32811531. PMCID: PMC7432540. https://doi.org/10.1186/s13287-020-01875-5
46. Meng F, Xu R, Wang S, et al. Human umbilical cord-de-rived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial. Signal Transduct Target Ther. 2020;5(1):172. PMID: 32855385. PMCID: PMC7450163. https://doi.org/10.1038/s41392-020-00286-5
47. Lanzoni G, Linetsky E, Correa D, et al. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial. Stem Cells Transl Med. 2021;10(5):660-673. PMID: 33400390. PMCID: PMC8046040. https://doi.org/10.1002/sctm.20-0472
Review
For citations:
Gilevich I.V., Polyakov I.S., Porhanov V.A., Storozhuk A.P., Zavgorodnyaya A.G., Kolomiytseva E.A., Sotnichenko A.S. Application of cells of cord blood and umbilical cord: achievements, challenges and perspectives. Innovative Medicine of Kuban. 2022;(2):67-76. (In Russ.) https://doi.org/10.35401/2541-9897-2022-25-2-67-76
Views:
700
Email this article 
